Company profile

Combioxin SA

More news about Combioxin SA

16.06.2023 09:30

FDA grants extended exclusivity for bacterial pneumonia treatment

Success

27.08.2021 14:03

Combioxin enters into licensing agreement for its treatment against severe pneumonia

Financing

03.05.2019 10:59

Combioxin announces milestone in the field of infectious diseases

Success

17.04.2018 10:59

Positive results from first-in-man trial for the treatment of Pneumonia

Success

Combioxin SA

Founded
2015

Kanton
Genève

Twitter
@Combioxin

Principal

Innosuisse

Swiss Venture Capital Report

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.

Register for more services

Partners

Gebert Rüf Stiftung

Swiss Entrepreneurs Foundation

UBS

Contributors

EPFL Innovation Park Foundation

IFJ

Innovaud

Kendris

Lichtsteiner Foundation

SICTIC

Startup Campus

Swiss Economic Forum

Swisscom

Swissnex

Switzerland Innovation

venturelab

W.A. De Vigier Stiftung

Supporters

Basel Area Business & Innovation

Business Angels Switzerland

ESA BIC Switzerland

StartAngels Network

Switzerland Global Enterprise

Technology Fund

Technopark Luzern

Technopark Winterthur

TECHNOPARK Zürich

University of Basel

USI Startup Centre

Supporters

Basel Area Business & Innovation

Business Angels Switzerland

EPFL Innovation Park Foundation

ESA BIC Switzerland

Gebert Rüf Stiftung

StartAngels Network

Swiss Entrepreneurs Foundation

Switzerland Global Enterprise

Switzerland Innovation

Technology Fund

Technopark Luzern

Technopark Winterthur

TECHNOPARK Zürich

University of Basel

USI Startup Centre

W.A. De Vigier Stiftung

By continuing to use this website you agree with our TERMS AND CONDITIONS